ENHERTU Reduced Risk of Death by 30% as 2L Therapy in Patients w/HER2+ Unresectable or Metastatic Gastric Cancer in ...

as well as published in The New England Journal of Medicine. At a median follow-up of 16.8 months for Enhertu and 14.4 months for Cyramza plus paclitaxel, the median overall survival was 14.7 months ...

WILMINGTON, DE — Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), combined with pertuzumab, delivered a highly ...

WILMINGTON, DE — Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when followed by paclitaxel, trastuzumab, and pertuzumab ...

Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer ...

Enhertu is part of a newer type of cancer treatment called antibody-drug conjugates (ADC). It works like a delivery system for medicine, even a "biologic missile." Imagine you're trying to deliver ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting ENHERTU is a specifically ...

Get Instant Summarized Text (Gist) Trastuzumab deruxtecan, known as Enhertu, has been approved in the UK for treating advanced HER2-positive cancers that are inoperable or have metastasized. This ...